Nutrition Last reviewed: June 28, 2026

Does high salt intake cause hypertension?

Strong Evidence
Confidence Score 80%

YES

Strong evidence from multiple meta-analyses, RCTs, and large cohort studies confirms that high sodium intake raises blood pressure and contributes to hypertension. The DASH-Sodium trial and INTERSALT study provide robust causal evidence. Salt sensitivity varies between individuals, but population-level effects are well-established.

The Verdict

Strong evidence from multiple meta-analyses, RCTs, and large cohort studies confirms that high sodium intake raises blood pressure and contributes to hypertension. The DASH-Sodium trial and INTERSALT study provide robust causal evidence. Salt sensitivity varies between individuals, but population-level effects are well-established.

What the Evidence Shows

The relationship between dietary sodium and blood pressure is among the most extensively studied in nutrition epidemiology. High sodium intake increases extracellular fluid volume, raises cardiac output, and over time contributes to vascular remodeling and arterial stiffness. The INTERSALT study (over 10,000 participants across 32 countries) demonstrated a clear positive association between sodium excretion and blood pressure across populations. The DASH-Sodium trial—a rigorously controlled feeding study—showed dose-response blood pressure reductions with sodium restriction at three levels, confirming causality independent of other dietary factors. Meta-analyses consistently estimate that reducing sodium intake by 4.4g/day (1,700mg sodium) lowers systolic blood pressure by approximately 4-5 mmHg in hypertensives and 2 mmHg in normotensives. The effect is greater in older adults, Black populations, and those with higher baseline blood pressure. At the population level, even modest sodium reduction (1g/day less) is estimated to prevent 5-7% of strokes and cardiovascular events. However, individual 'salt sensitivity' varies genetically—approximately 30-50% of hypertensives and 15-25% of normotensives are salt-sensitive. The debate around optimal sodium intake continues, with some evidence suggesting very low sodium (<3g/day) may also increase cardiovascular risk (J-shaped curve), though this finding is controversial and may reflect reverse causation or measurement error.

Evidence Quality

8

Meta-Analyses

12

RCTs

20

Observational

Important Caveats

  • ⚠️ Salt sensitivity varies significantly between individuals (genetic component)
  • ⚠️ J-shaped curve debate: very low sodium may also carry risk
  • ⚠️ 24-hour urine collection is the gold standard but rarely used in cohort studies
  • ⚠️ Processed food sodium is difficult to separate from other dietary factors
  • ⚠️ Potassium intake modifies sodium's effect on blood pressure

Population Studied

General adult populations worldwide; INTERSALT included 10,079 adults across 32 countries; DASH-Sodium included 412 adults; multiple meta-analyses cover diverse populations

Dosage

Average intake: 9-12g salt/day (3,500-4,800mg sodium) globally; WHO recommends <5g salt/day (<2,000mg sodium); DASH-Sodium tested 3.3g, 6.6g, and 9.9g salt/day

Duration

DASH-Sodium: 30 days per sodium level; cohort studies: 5-20+ year follow-up; blood pressure effects measurable within 1-4 weeks of reduction

Supporting Studies (4)

Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials

Meta-Analysis

He FJ, Li J, MacGregor GA. · BMJ (2013)

Cochrane meta-analysis of 34 RCTs (3,230 participants) found that reducing sodium by 4.4g/day lowered blood pressure by 4.18/2.06 mmHg (systolic/diastolic), with larger effects in hypertensives (-5.39/-2.82 mmHg).

View paper (DOI) →

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet

RCT

Sacks FM, Svetkey LP, Vollmer WM, et al. · New England Journal of Medicine (2001)

The DASH-Sodium trial demonstrated a clear dose-response: reducing sodium from high (150 mmol/d) to low (50 mmol/d) lowered systolic BP by 6.7 mmHg in normotensives and 11.5 mmHg in hypertensives on the control diet.

View paper (DOI) →

Sodium intake and all-cause mortality over 20 years in the Trials of Hypertension Prevention

RCT

Cook NR, Appel LJ, Whelton PK. · Journal of the American College of Cardiology (2016)

Twenty-year follow-up of sodium reduction trials found that each 1000mg/day reduction in sodium intake was associated with 30% lower cardiovascular mortality, providing the longest outcome data linking sodium reduction to hard endpoints.

View paper (DOI) →

Global sodium consumption and death from cardiovascular causes

Meta-Analysis

Mozaffarian D, Fahimi S, Singh GM, et al. · New England Journal of Medicine (2014)

Global analysis estimated that 1.65 million cardiovascular deaths annually are attributable to sodium intake above 2g/day, with the highest burden in Asian countries with high dietary sodium.

View paper (DOI) →

Contradicting Studies (2)

Urinary sodium and potassium excretion, mortality, and cardiovascular events

Observational

O'Donnell M, Mente A, Rangarajan S, et al. · New England Journal of Medicine (2014)

The PURE study (101,945 participants) found a J-shaped association: both high (>7g/day) and low (<3g/day) sodium excretion were associated with increased cardiovascular events and mortality, suggesting very low sodium may also be harmful.

Why this disagrees:

This suggests current WHO guidelines (<2g sodium/day) may be too aggressive, and that moderate intake (3-5g/day) may be optimal. However, critics note the PURE study used spot urine rather than 24-hour collections, potentially introducing measurement bias at both extremes.

View paper (DOI) →

Sodium intake and cardiovascular mortality: a lack of evidence from systematic reviews of randomized controlled trials

Meta-Analysis

Graudal NA, Hubeck-Graudal T, Jurgens G. · Cochrane Database of Systematic Reviews (2020)

Updated Cochrane review confirmed sodium reduction lowers blood pressure but found insufficient evidence from RCTs to conclude that sodium reduction reduces cardiovascular mortality or events in the general population.

Why this disagrees:

While blood pressure reduction is confirmed, the translation to reduced cardiovascular events relies primarily on observational data and blood pressure as a surrogate endpoint. Long-term RCTs with mortality endpoints are lacking, partly due to ethical and practical challenges of sustained dietary trials.

View paper (DOI) →
Share:
Was this helpful?

Related Claims